{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:08:52Z","timestamp":1789470532844,"version":"build-2803163510"},"reference-count":70,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1135991"],"award-info":[{"award-number":["1135991"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA1104470"],"award-info":[{"award-number":["R01DA1104470"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>There is limited evidence on the relationship between retention in opioid agonist treatment for opioid dependence and characteristics of treatment prescribers. This study estimated retention in buprenorphine and methadone treatment and its relationship with person, treatment and prescriber characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective longitudinal study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>New South Wales, Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>People entering the opioid agonist treatment programme for the first time between August 2001 and December 2015.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Time in opioid agonist treatment (primary outcome) was modelled using a generalized estimating equation model to estimate associations with person, treatment and prescriber characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>The impact of medication type on opioid agonist treatment retention reduced over time; the risk of leaving treatment when on buprenorphine compared with methadone was higher among those who entered treatment earlier [e.g. 2001\u201303: odds ratio (OR)\u00a0=\u00a01.59, 95% confidence interval (CI)\u00a0=\u00a01.45\u20131.75] and lowest among those who entered most recently (2013\u201315: OR\u00a0=\u00a01.23, 95% CI\u00a0=\u00a01.11\u20131.36). In adjusted analyses, risk of leaving was reduced among people whose prescriber had longer tenure of prescribing (e.g. 3 versus 8\u00a0years: OR\u00a0=\u00a00.94, 95% CI\u00a0=\u00a00.93\u20130.95) compared with prescribers with shorter tenure. Aboriginal and Torres Strait Islander people, being of younger age, past\u2010year psychosis disorder and having been convicted of more criminal charges in the year prior to treatment entry were associated with increased risk of leaving treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In New South Wales, Australia, retention in buprenorphine treatment for opioid dependence, compared with methadone, has improved over time since its introduction in 2001. Opioid agonist treatment retention is affected not only by characteristics of the person and his or her treatment, but also of the prescriber, with those of longer prescribing tenure associated with increased retention of people in opioid agonist treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.15514","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T11:05:40Z","timestamp":1620817540000},"page":"3139-3152","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15\u2010year retrospective cohort study"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9778-0386","authenticated-orcid":false,"given":"Chrianna","family":"Bharat","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-4963","authenticated-orcid":false,"given":"Sarah","family":"Larney","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Montr\u00e9al and Centre de Recherche du CHUM  Montreal Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5919-372X","authenticated-orcid":false,"given":"Sebastiano","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-9056","authenticated-orcid":false,"given":"Timothy","family":"Dobbins","sequence":"additional","affiliation":[{"name":"School of Population Health, UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-4598","authenticated-orcid":false,"given":"Nicola R.","family":"Jones","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-459X","authenticated-orcid":false,"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School University of Bristol  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-8470","authenticated-orcid":false,"given":"Natasa","family":"Gisev","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Pharmacology University of Adelaide  Adelaide SA Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8513-2218","authenticated-orcid":false,"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, UNSW Sydney  Sydney NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.04.015"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903037168"},{"key":"e_1_2_9_4_1","volume-title":"Model List of Essential Medicines 21st List, 2019 [internet]","author":"World Health Organization (WHO)","year":"2019"},{"key":"e_1_2_9_5_1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick R. P.","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14012"},{"key":"e_1_2_9_8_1","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta\u2010analysis","volume":"345","author":"MacArthur G. J.","year":"2012","journal-title":"BMJ [internet]"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(19)30060-X"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14059"},{"key":"e_1_2_9_11_1","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta\u2010analysis of cohort studies","volume":"357","author":"Sordo L.","year":"2017","journal-title":"BMJ [internet]"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(97)00099-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00080.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00354.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.05.010"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12834"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.12.009"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.05.002"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.01.013"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139942"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2014.05.007"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-017-0134-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14398"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017751913"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.08.024"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02538.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2005.11.020"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000263"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12896"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.12.010"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2014.957769"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2012.03.002"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550880802324382"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.04.010"},{"key":"e_1_2_9_37_1","article-title":"Factors associated with methadone treatment duration: a Cox regression analysis","volume":"10","author":"Lin C.\u2010K.","year":"2015","journal-title":"PLoS One [Internet]"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp186"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2013.825032"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2012.694516"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2019.1622649"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(00)00124-0"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10503309812331332527"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000277657"},{"key":"e_1_2_9_45_1","unstructured":"Australian Institute of Health and Welfare (AIHW).National Opioid Pharmacotherapy Statistics Annual Data Collection 2019. Report no.: 266 [internet]. Canberra: AIHW;2020. Available at:https:\/\/www.aihw.gov.au\/reports\/alcohol\u2010other\u2010drug\u2010treatment\u2010services\/national\u2010opioid\u2010pharmacotherapy\u2010statistics\u20102019(accessed 10 July 2020)."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108464"},{"key":"e_1_2_9_47_1","volume-title":"NSW Policy for the Use of Buprenorphine in the Treatment of Opioid Dependence","author":"New South Wales Department of Health","year":"2001"},{"key":"e_1_2_9_48_1","volume-title":"National Opioid Pharmacotherapy Statistics Annual Data Collection 2019","author":"Australian Institute of Health and Welfare","year":"2020"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025204"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.05.021"},{"key":"e_1_2_9_51_1","unstructured":"Australian Bureau of Statistics.Australian Statistical Geography Standard (ASGS) Remoteness Structure [internet].2018[cited 2020 May 1]. Available at:https:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/mf\/1270.0.55.005(accessed 1 May 2020)."},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwk020"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2001.00120.x"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_2_9_55_1","article-title":"R: A Language and Environment for Statistical Computing [internet]. Vienna, Austria: R Foundation for Statistical","author":"R Core Team","year":"2019","journal-title":"Computing"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.22.2469"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000219050.33008.61"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)10510-7"},{"key":"e_1_2_9_60_1","unstructured":"NSW Ministry of Health.NSW Clinical Guidelines: Treatment of Opioid Dependence\u20142018. NSW Australia: NSW Ministry of Health;2018."},{"key":"e_1_2_9_61_1","unstructured":"NSW Ministry of Health.Opioid Treatment Program: Clinical Guidelines for Methadone and Buprenorphine Treatment. NSW Australia: NSW Ministry of Health;2006."},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30373-X"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-9-20"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2008.06.006"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-017-0541-4"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034389"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.12.021"},{"key":"e_1_2_9_68_1","volume-title":"Polygon: the Many Sides to the Australian Opioid Pharmacotherapy Maintenance System","author":"Ritter A.","year":"2009"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-9-32"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2012.00472.x"},{"key":"e_1_2_9_71_1","unstructured":"IrvineK.Hall R. TaylorL.Centre for Health Record Linkage\u2010Quality Assurance: expanding access to linked population data for NSW and the ACT Australia2020.https:\/\/doi.org\/10.23889\/ijpds.v4i2.1142[internet] [cited 2020 Aug 17]. Available at:https:\/\/www.cherel.org.au\/quality\u2010assurance(accessed 17 Aug 2020)."}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15514","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:22:57Z","timestamp":1780989777000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/add.15514"],"URL":"https:\/\/doi.org\/10.1111\/add.15514","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"2020-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}